BACKGROUND MDR-TB caused an estimated 600,000 new TB cases and 240,000 deaths in 2016 and MDR-TB accounts for 4.1% of all new TB cases and 19% of previously treated cases worldwide. Globally, most MDR-TB cases occur in South America, Southern Africa, India, China, and the former Soviet Union. Rapid detection of drug resistance of M. tuberculosis and MDR-TB strains ensures effective treatment of TB patients and limits further development of resistance to additional drugs. The GeneXpert test is a molecular test for TB which diagnoses TB by detecting the presence of TB bacteria, as well as testing for resistance to the drug Rifampicin. In India, where this test is starting to be widely used, it is known as the CBNAAT. The full name of the CBNAAT test is the Cartridge Based Nucleic Acid Amplification Test. The objective of the study is to assess the performance of GeneXpert MTB/RIF as an initial diagnostic tool for the diagnosis of Mycobacterium tuberculosis and Rifampicin Resistance. METHODS The RNTCP programme is being strictly followed and carried out in Shri B.M. Patil Medical college Hospital, BLDE University Vijayapur Karnataka. Samples of patients with symptoms suggestive of tuberculosis including, suspected new TB cases, old TB cases and on treatment TB cases, were received from all the Primary Healthcare Canters, and all other Healthcare Centres including two Medical College Hospitals of Vijayapur district. Samples collected under this programme were analysed by GeneXpert Test at District TB Hospital CBNAAT center Vijayapur, Karnataka. A retrospective study was conducted from 1 January 2016 to 31 December 2018. The samples were subjected to GeneXpert MTB/ RIF manufactured by Cepheid, France for the detection of M. tuberculosis and then rifampicin resistance in them. Data analysis was done using SPSS Version 22.0.0.0. RESULTS In this study a total of 4978 patients' samples was processed for CBNAAT test. Out of these cases, MTB was detected in 1186 (23.82%), Rifampicin Resistance (RR) was detected in 165 (13.91%) cases. Among these 165 MTB-RR cases, the MTB detection level was, 50 (30.30%) High, 65 (39.39%) Medium, 26 (15.79%) Low, 16 (9.69%) Very Low & 8 (4.84%) Intermediate. Out of 4978 cases 427 (8.58%) were HIV positive, among these HIV positive cases MTB was detected in 51 (12%) & RR detected in 13 (25.50%) cases. CONCLUSIONS The implementation of the GeneXpert MTB/RIF assay in programmatic management of TB & MDR-TB in RNTCP has dramatically improved the rapid diagnosis of tuberculosis & drug resistance, especially in People Living with HIV/AIDS (PLWHA).